Damora Therapeutics, Inc.

NASDAQ:DMRA

Biotechnology

Healthcare
$22.98 +0.34%

+$0.07 today

Market cap
$1.42B
Beta
1.48
P/E (TTM)
-0.1
EPS (TTM)
-$177.15
52W Low $2.45High $38.33

Volume 0.58M

Average 0.33M

DMRA Net Receivables

Amounts owed to the company by customers and others, net of allowances for uncollectible accounts.

Damora Therapeutics, Inc.NASDAQ: DMRA

Net Receivables · Q1 FY2026 · quarter ended Mar 2026

Net receivables falls 2.5% from a year ago

Net receivables stood at $894K at the end of Q1 FY2026, down 2.5% from a year earlier and down 0.6% from the prior quarter. Over 3 fiscal years it compounded at -13.3% a year.

Context

  • Net receivables amounted to 0.2% of total assets at the end of Q1 FY2026, down 5.8 pp from a year earlier.
  • Net receivables increased in 2 of the last 3 fiscal years.

What to watch

Whether net receivables keeps falling in the next quarterly balance sheet after a -2.5% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$894K-0.6% QoQ
Last fiscal yearDec 2025
$899K+2.0% YoY
Year agoMar 2025
$917K-2.5% since
Net Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-2.5%——
1 year+2.0%——
3-year CAGR-13.3%——
5-year CAGR——
10-year CAGR——

Net Receivables history

USD · from the balance sheet

Latest · FY2025
899K USD
Year-over-year change
+2.0%
4-year CAGR
-20.8%

Net Receivables vs competitors

How DMRA compares with its peers on the latest reported figures

  • DMRA's Mar 2026 net receivables of $894K is the 7th highest of the 9 companies compared; the peer median is $23.83M.
  • Its year-over-year change of -2.5% is the 6th highest of 7, against a peer median of +29.0%.
  • Net receivables amounts to 0.2% of total assets for DMRA, versus a peer median of 4.6%.
DMRA Competitors Peer median
Net Receivables for DMRA and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
GMABGenmab A/SJun 2026$1.28B +28.3%-41.4%10.2%
INCYIncyte CorporationJun 2026$1.13B +33.5%+16.7%14.3%
RIGLRigel Pharmaceuticals, Inc.Mar 2026$49.95M +20.2%+8.7%9.9%
GERNGeron CorporationMar 2026$44.1M +29.8%+131.9%8.3%
QUREuniQure N.V.Mar 2026$3.56M +41.2%-61.5%0.5%
KROSKeros Therapeutics, Inc.Mar 2026$2.96M -84.7%+96.4%0.9%
DMRADamora Therapeutics, Inc.Mar 2026$894K -2.5%-13.3%0.2%
IRONDisc Medicine, Inc.Sep 2026$0 ——0.0%
COAGHemab Therapeutics Holdings, Inc. Common StockJun 2026$0 ——0.0%
Peer median (excluding DMRA) $23.83M+29.0%+12.7%4.6%

Competitors are the stored peer set for DMRA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents62.56M32.79M21.47M14.18M257.62M
Short-term Investments37.63M27.44M11.69M00
Net Receivables2.28M1.38M1.72M881K899K
Inventory00000
Other Current Assets5.9M1.5M1.13M1.19M1.32M
Total Current Assets110.1M63.91M36.77M16.84M260.42M
Property, Plant & Equipment (Net)1.04M1.17M325K130K104K
Goodwill00000
Intangible Assets00000
Long-term Investments9.05M5.83M000
Tax Assets00000
Other Non-current Assets2.03M2.28M1.13M163K0
Total Non-current Assets12.11M9.28M1.45M293K104K
Total Assets122.22M73.19M38.23M17.13M260.53M
Account Payables1.53M3.35M1.7M377K444K
Short-term Debt399K476K183K12K0
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities2.01M6.68M2.96M604K1.52M
Total Current Liabilities4.54M11.11M5.83M1.2M20.07M
Long-term Debt0001.36M0
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities00043K28K
Total Non-current Liabilities448K328K66K1.46M81K
Total Liabilities4.99M11.44M5.9M2.66M20.15M
Common Stock00000
Retained Earnings(156.11M)(217.74M)(256.08M)(277.52M)(487.36M)
Accumulated OCI(320K)(244K)380K97K802K
Other Stockholders Equity00000
Minority Interest00000
Total Equity117.22M61.75M32.33M14.47M240.38M
Total Debt847K804K249K1.43M68K
Net Debt(61.72M)(31.98M)(21.22M)(12.74M)(257.56M)

Damora Therapeutics, Inc.

NASDAQ:DMRA

Intrinsic Alpha fair value

Locked

Current Price

$22.98

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.